Publicaciones en colaboración con investigadores/as de Medical University of Vienna (102)

2023

  1. Alginate sulfate-nanoparticles loaded with hepatocyte growth factor and insulin-like growth factor-1 improve left ventricular repair in a porcine model of myocardial ischemia reperfusion injury

    European Journal of Pharmaceutics and Biopharmaceutics, Vol. 184, pp. 83-91

  2. Artificial intelligence-based pathology as a biomarker of sensitivity to atezolizumab-bevacizumab in patients with hepatocellular carcinoma: a multicentre retrospective study

    The Lancet. Oncology, Vol. 24, Núm. 12, pp. 1411-1422

  3. Correction: “The 5th edition of The World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms” Leukemia. 2022 Jul;36(7):1720–1748 (Leukemia, (2022), 36, 7, (1720-1748), 10.1038/s41375-022-01620-2)

    Leukemia

  4. ESGO/ESTRO quality indicators for radiation therapy of cervical cancer

    Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, Vol. 183, pp. 109589

  5. ESGO/ESTRO quality indicators for radiation therapy of cervical cancer

    International Journal of Gynecological Cancer, Vol. 33, Núm. 6, pp. 862-875

  6. ESGO/ESTRO/ESP Guidelines for the management of patients with cervical cancer – Update 2023

    Radiotherapy and Oncology, Vol. 184

  7. European Association of Neuro-Oncology (EANO) guidelines for treatment of primary central nervous system lymphoma (PCNSL)

    Neuro-oncology, Vol. 25, Núm. 1, pp. 37-53

  8. Exploring the EVolution in PrognOstic CapabiLity of MUltisequence Cardiac MagneTIc ResOnance in PatieNts Affected by Takotsubo Cardiomyopathy Based on Machine Learning Analysis: Design and Rationale of the EVOLUTION Study

    Journal of Thoracic Imaging, Vol. 38, Núm. 6, pp. 391-398

  9. GIInger predicts homologous recombination deficiency and patient response to PARPi treatment from shallow genomic profiles

    Cell Reports Medicine, Vol. 4, Núm. 12

  10. Impact of adjuvant sorafenib treatment after local ablation for HCC in the phase II SORAMIC trial

    JHEP Reports, Vol. 5, Núm. 5

  11. Impact of body composition in advanced hepatocellular carcinoma: A subanalysis of the SORAMIC trial

    HEPATOLOGY COMMUNICATIONS, Vol. 7, Núm. 6

  12. Non-hypervascular hepatobiliary phase hypointense lesions detected in patients with hepatocellular carcinoma: a post hoc analysis of SORAMIC trial to identify risk factors for progression

    European Radiology, Vol. 33, Núm. 1, pp. 493-500

  13. Prognostic factors in patients with uterine sarcoma: The SARCUT study

    International Journal of Gynecological Cancer, Vol. 33, Núm. 6, pp. 897-904

  14. Prognostic role of radiomics-based body composition analysis for the 1-year survival for hepatocellular carcinoma patients

    Journal of Cachexia, Sarcopenia and Muscle, Vol. 14, Núm. 5, pp. 2301-2309

  15. The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 24th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2022

    ESMO Open, Vol. 8, Núm. 3

  16. Uncertainties and controversies in axillary management of patients with breast cancer

    Cancer Treatment Reviews, Vol. 117